Skip to main content
Premium Trial:

Request an Annual Quote

William Janzen, Rudi Pauwels, Wilson Totten, David Stone

Amphora Discovery this week announced the appointment of William Janzen, a company co-founder, as president and chief operating officer.
Prior to his promotion, Janzen served as Amphora’s vice president of operations and chief technology officer. Prior to co-founding Amphora, Janzen spent 18 years in pharmaceutical R&D at Eli Lilly and Sphinx Pharmaceuticals.

Galapagos this week said it has added Rudi Pauwels as an independent, non-executive board member.
Pauwels is a co-founder of Galapagos, as well as Tibotec (now a part of Johnson & Johnson) and Virco.
Galapagos also said that Wilson Totten and David Stone stepped down as board members in December. Totten had served as a non-executive board member since Oct. 2004, while Stone had served since Galapagos’ Oct. 2005 acquisition of BioFocus.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.